Online Inquiry
HER2/ErbB2 Antibody
SPA-05003
| Size | Price |
| 100 µg | Online Inquiry |
| 25 µg | Online Inquiry |
| More Options | Online Inquiry |
| Target Information | |
|---|---|
| Target Name | HER2/ErbB2 |
| Gene Abbr. | ERBB2 |
| Gene ID | 2064 |
| Full Name | erb-b2 receptor tyrosine kinase 2 |
| Alias | CD340, HER-2, HER-2/neu, HER2, MLN 19 |
| Introduction | The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity. While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members. Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase. ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway. |
| Product Details | |
|---|---|
| Host | Rabbit |
| Clonality | Monoclonal |
| Clone No. | Available upon request. |
| Isotype | IgG Kappa |
| Immunogen | A431 cells (human epidermoid carcinoma) (over)expressing EGFR. |
| Usage | |
|---|---|
| Application | ELISA, FC, IHC |
| Dilutions | ELISA (1:100-1:2000); Flow Cytometry (1:10-1:1000); Immunohistochemistry (1:10-1:500) |
| MW(KDa) | 185 |
| Reactivity | Human |
| Specificity | Oncogenic protein Her-2/neu (erbB-2), a member of the family of epidermal growth factor (EGF) receptors, overexpressed in 30% of invasive breast cancers and 70% of ductal carcinomata in situ, in a small percentage of melanomas, and in other malignancies originating from various organs, including ovary, kidney, colon, and bladder. |
| Storage & Handling | |
|---|---|
| Storage Buffer | PBS. |
| Preservative | 0.02% Proclin 300 |
| Storage Temp. | Store at 4 °C for up to 3 months. For longer storage, aliquot and store at -20 °C. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.